

- 7:45 a.m. 70 SECONDARY TRANSURETHRAL RESECTION FOR T1 BLADDER CANCER DECREASES RISK OF PROGRESSION**
Eric Umbreit, MD; Mark Shimko, MD; R. Houston Thompson, MD; Igor Frank, MD
Mayo Clinic
Presented By: Eric Umbreit, MD
- 7:50 a.m. 71 FORMAL RESTAGING PROCEDURE FOLLOWING TREATMENT OF HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)**
Andrew Lightfoot, MD; Henry Rosevear, MD; Kenneth Nepple, MD; Michael O'Donnell, MD
University of Iowa
Presented By: Andrew Lightfoot, MD
- 7:55 a.m. 72 THE SURVIVAL BENEFITS OF REPEAT BLADDER TUMOR RESECTION**
Ted Skolarus, MD; Zaojun Ye, MS; Brent Hollenbeck, MD, MS
Department of Urology, University of Michigan
Presented By: Ted Skolarus, MD
- 8:00 a.m. 73 FACTORS AFFECTING RESPONSE TO BCG+INTERFERON ALPHA-2B (IFN-?) IN PATIENTS WITH UROTHELIAL CARCINOMA IN SITU (CIS)**
Henry Rosevear, MD; Andrew Lightfoot, MD; Michael O'Donnell, MD
University of Iowa
Presented By: Henry Rosevear, MD
- 8:05 a.m. 74 OUTCOMES OF RADICAL CYSTECTOMY AFTER FAILED INTRAVESICAL IMMUNOTHERAPY FOR PATIENTS WITH PREVIOUSLY TREATED PROSTATE CANCER**
Manoj Rao, MD¹; Gautam Jayram, MD²; Chandy Ellimoottil, MD¹; Cory M Hugen, MD¹; Marcus L. Quek, MD, FACS¹; Robert C Flanigan, MD, FACS¹; Gary D Steinberg, MD, FACS²
¹Loyola University Medical Center; ²University of Chicago
Presented By: Manoj Rao, MD
- 8:10 a.m. 75 CHANGING PRACTICE PATTERNS IN THE MANAGEMENT OF HIGH GRADE NON-MUSCLE-INVASIVE BLADDER CANCER**
Lauren Marquette¹; J Stephen Jones, MD²; Krishnan Venkatesan¹; Amarnath Rambhatla, MD¹; Nivedita Dhar, MD¹
¹Wayne State University; ²Cleveland Clinic Foundation
Presented By: Krishnan Venkatesan

- 8:15 a.m. 76 RISK FACTORS FOR RECURRENCE FOLLOWING RADICAL CYSTECTOMY FOR PATHOLOGIC NODE-NEGATIVE BLADDER CANCER**
Cory Hugen, MD; Anthony Polcari, MD; MaryPat FitzGerald, MD; Casey Dauw; Robert Flanigan, MD; Marcus Quek, MD
Loyola University Chicago
Presented By: Cory Hugen, MD
- 8:20 a.m. 77 A HISTORY OF PROSTATE EXTERNAL BEAM RADIATION PRIOR TO RADICAL CYSTECTOMY CONFERS A WORSE OUTCOME THAN PRIOR RADICAL PROSTATECTOMY**
Manoj Rao, MD¹; Gautam Jayram, MD²; Marcus L. Quek, MD, FACS¹; Robert C. Flanigan, MD, FACS¹; Gary D. Steinberg, MD, FACS²
¹Loyola University Medical Center; ²University of Chicago
- 8:25 a.m. 78 LONG-TERM ONCOLOGIC OUTCOMES OF PATIENTS WITH STAGE PT0 FOLLOWING RADICAL CYSTECTOMY**
Manoj Rao, MD; Cory M. Hugen, MD; Anthony Polcari, MD; Ahmer Farooq, DO; Robert C. Flanigan, MD, FACS; Marcus L. Quek, MD, FACS
Loyola University Medical Center
Presented By: Manoj Rao, MD
- 8:30 a.m. 79 ADJUVANT CHEMOTHERAPY FOLLOWING CYSTECTOMY REDUCES RECURRENCE IN LOCALLY ADVANCED UROTHELIAL CARCINOMA**
Matthew Tollefson, MD; Manish Kohli, MD; Sara Farmer, MS; Christine Lohse, MS; Igor Frank, MD
Mayo Clinic
Presented By: Matthew Tollefson, MD
- 8:35 a.m. 80 LONG-TERM COMPLICATIONS OF CONDUIT URINARY DIVERSION: ANALYSIS WITH 15 YEARS OF FOLLOW UP.**
Mark Shimko; Matthew Tollefson, MD; Eric Umbreit, MD; Sara Farmer; Igor Frank, MD
Mayo Clinic
Presented By: Mark Shimko
- 8:40 a.m. – 8:55 a.m. Q&A**